Rituximab Biosimilar - Anti-MS4A1 mAb - Research Grade
Source
DrugBank DB00073
Species
Human
Expression system
Mammalian cells
Molecular weight
143kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Rituximab,Rituximab,MS4A1,anti-MS4A1
Reference
PX-TA1010
Note
For research use only. Not suitable for human use.
Isotype
IgG1
Clonality
Monoclonal Antibody
Description of Rituximab Biosimilar - Anti-MS4A1 mAb - Research Grade
General information about Rituximab
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. This product is for research use only.
Rhomberg-Kauert J, Karlsson M, Thiagarajan D, Kallas T, Karlsson F, Fredriksson S, Dahlberg J and Martinez Barrio A (2024) Using adjusted local assortativity with Molecular Pixelation unveils colocalization of membrane proteins with immunological significance. Front. Immunol. 15:1309916. doi: 10.3389/fimmu.2024.1309916
Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Sandrine Jayne, Martin J.S. Dyer, Harriet S. Walter, Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20, Blood, Volume 144, Supplement 1, 2024, Page 5826, ISSN 0006-4971, https://doi.org/10.1182/blood-2024-203884.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Rituximab Biosimilar – Anti-MS4A1 mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.